Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer
Berend J. van der Wilk(Erasmus MC Cancer Institute), J. Jan B. van Lanschot(Erasmus MC Cancer Institute), Daan Nieboer(Erasmus MC), Sung‐Bae Kim(Ulsan College), Heidi Furlong(The University of Texas MD Anderson Cancer Center), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Sjoerd M. Lagarde(University of Amsterdam), Rita Alfieri(Istituto Oncologico Veneto), Jong H. Kim(Seoul National University), Ben M. Eyck(Erasmus MC Cancer Institute), Carlo Castoro(Humanitas University), Bas P. L. Wijnhoven(Inserm), T. N. Walsh(Connolly Hospital Blanchardstown), Wayne L. Hofstetter(The University of Texas MD Anderson Cancer Center), Guillaume Piessen(Centre Hospitalier Universitaire de Lille)
Cited by 67
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.7k
Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus
|New England Journal of Medicine|2002|1.6k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k